Amneal Pharmaceuticals, Inc.
AMRX
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $5.6B
$17.44
▼ -2.41%
P/E
30.73
Mkt Cap
$5.6B
52-Wk Range
$9.49–$19.26
52-Week Range
$9.49 - $19.26
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 79.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified product portfolio across generics and specialty pharmaceuticals reducing revenue concentration risk
- Established government contracting relationships through AvKARE segment with DoD and VA providing stable revenue
- Integrated manufacturing capabilities across multiple dosage forms and geographies enabling complex product development
- Branded specialty medications with patent protection and higher margins in CNS and endocrinology markets
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Increasing demand for generic pharmaceuticals as healthcare systems seek cost-effective treatment options
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Hot
+27.2% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying AMRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $0.30 vs $0.22 consensus (+34.8% surprise). Revenue of $796.2M vs $768.2M expected (+3.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+34.8%
Revenue trend · last 8Q
—
+18%
+5%
+3%
+12%
+11%
-100%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$702.5M
$730.5M
$695.4M
$724.5M
$784.5M
$814.3M
$0
$796.2M
Margins · last 8Q
Gross
42.0%
Operating
-0.2%
Profit
7.2%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Jul 31, 2026
vs Industry
How AMRX stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related